| Coronary heart disease
Caduet vs Praluent
Side-by-side clinical, coverage, and cost comparison for coronary heart disease.Deep comparison between: Caduet vs Praluent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPraluent has a higher rate of injection site reactions vs Caduet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Praluent but not Caduet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caduet
Praluent
At A Glance
Oral
Daily
Calcium channel blocker + HMG-CoA reductase inhibitor
SC injection
Every 2-4 weeks
PCSK9 inhibitor
Indications
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
- Hyperlipidemia
- Heterozygous familial hypercholesterolemia [HeFH]
- Homozygous familial hypercholesterolemia [HoFH]
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
- Coronary heart disease
- Myocardial Infarction
- Coronary heart disease
- Cerebrovascular accident
- Angina, Unstable
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
Dosing
Hypertensive disease Amlodipine 5 mg orally once daily (initial); max 10 mg once daily; start at 2.5 mg in elderly, fragile, small adult, pediatric (>6 years), or patients with hepatic insufficiency.
Stable angina, Angina Pectoris, Variant Amlodipine 5-10 mg orally once daily; most patients require 10 mg for adequate effect.
Coronary Artery Disease Amlodipine 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.
Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia, Diabetes Mellitus, Non-Insulin-Dependent, Coronary heart disease Atorvastatin 10-80 mg orally once daily; start at 40 mg if LDL-C reduction >45% is required.
Heterozygous familial hypercholesterolemia [HeFH] Atorvastatin 10-80 mg orally once daily in adults; 10-20 mg once daily in pediatric patients >=10 years.
Homozygous familial hypercholesterolemia [HoFH] Atorvastatin 10-80 mg orally once daily in adults and pediatric patients >=10 years; starting dose 10-20 mg once daily.
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to amlodipine, atorvastatin, or any excipient in CADUET, including reactions such as anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis
- Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
Adverse Reactions
Most common Edema, dizziness, flushing, palpitations, nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Rhabdomyolysis, myositis, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, gynecomastia
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Pharmacology
CADUET combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance and blood pressure, with atorvastatin, a selective, competitive HMG-CoA reductase inhibitor that lowers plasma cholesterol by reducing cholesterol synthesis in the liver and increasing hepatic LDL receptor expression.
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caduet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Praluent
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Caduet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Praluent
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Caduet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Praluent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Caduet.
$50/momo
MyPraluent Copay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaduetView full Caduet profile
PraluentView full Praluent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.